Retatrutide is a novel triple agonist peptide that activates three incretin and related receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Developed by Eli Lilly, Retatrutide represents an evolution beyond dual agonists like Tirzepatide. The triple-receptor activation provides synergistic effects on weight loss and glucose control. GLP-1 and GIP activation enhances insulin secretion and satiety, while glucagon receptor agonism increases energy expenditure and hepatic fat oxidation. Phase 2 clinical trials showed unprecedented weight loss of up to 24% at higher doses, making it one of the most effective anti-obesity compounds in development.
| Research Status | Phase 3 trials |
|---|---|
| Half-Life | ~6 days |
| Administration | Subcutaneous injection |
| Typical Dosage | 1-12 mg weekly |
| Molecular Weight | Approximately 4,000-5,000 Da |
| Molecular Formula | Proprietary (complex modified peptide) |
Activates three receptor systems (GIP, GLP-1, glucagon) for maximum metabolic effects.
All information is presented for Research Use Only (RUO). Not medical advice.